A Pilot Study to Determine the Optimal Finger for Hypertension and Preeclampsia Assessment Using Pulse Oximeter Collection

Principal Investigator: Dr. Kenneth I. Lim

Primary Contact: Dr. Mohamed Elgendi, Mining for Miracles Postdoctoral Fellow, 604-875-2723 Email: mohamed.elgendi@cw.bc.ca

About the study: Hypertensive disorders of pregnancy such as preeclampsia increase the risk of life-ending and life-altering complications for both the mother and her unborn baby. Oxygen levels in pregnant women are measured using a non-invasive and safe machine called the pulse oximeter to measure hypertension. The oxygen level is measured by placing a probe on a woman’s finger for one minute, and the information collected through this method is used for patient monitoring and diagnosis of pregnancy-related complications.

This research study is being done because, at present, there are no guidelines outlining the best finger to use for measuring the oxygen saturation in the blood in pregnant women. It might be that different fingers of the hand provide different quality of information, and it is important to identify which finger provides the highest quality of information so that clinicians can make more accurate diagnoses. Signal patterns will also be looked at to see if it is predictive of pregnancy outcomes.

Why is this research important? Collecting high-quality signals from the most appropriate finger will enhance current care models by helping clinicians make a more accurate diagnosis, improve early prediction of complications, and enable timely patient management in health care settings and around the world where this technology is used.

Study status: Recruiting, aim to recruit 200 women.

Who can participate? For this study, we will recruit women who have no hypertension and those who have hypertension developed during pregnancy. These women will be compared in the data analysis, and will also be looked at according to how many weeks gestation they are. You may be able to participate in this study if:
• You are pregnant at 20–40 weeks gestation
• You are 20 years of age or older
• You have a singleton pregnancy
• You are delivering at BC Women’s Hospital

Co-Investigators: Dr. Rabab Ward, Dr. Mohamed Elgendi, Dr. Judy Needham, Dr. Jayson Potts

Funded by: BC Children’s Hospital Research Institute
Partners: University of British Columbia, BC Women’s Hospital + Health Centre

Consent Form: of-consent-form-final__oct-31-2016-v2

The Impact of Prenatal Screening for Fetal Aneuploidy on Maternal-Infant Bonding – (Pre-MIB) Study

Principal Investigator: Catriona Hippman

Primary Contact: Nicole Prestley, Research Manager, 604-875-2424 ext 4956, Nicole.Prestley@cw.bc.ca

About the study: The purpose of this study is to assess how the option to have prenatal genetic screening for chromosome abnormalities can impact maternal-infant bonding during pregnancy. Chromosome abnormalities take place when an abnormal number of chromosomes are within a cell, which is known to be the cause of certain birth defects. Maternal-infant bonding (MIB) is the term used to describe the affectionate relationship that develops between a mother and her fetus/infant. The study involves participants completing a questionnaire and interview, with a total time commitment of 1 hour and 30 minutes.

Why is this research important? A strong MIB has been known to promote healthy lifestyle choices during pregnancy and positive longer-term consequences for later maternal-child interactions. MIB can be threatened by prenatal stress, and prenatal stress can be experienced during the prenatal genetic screening process.  It is hoped that the results from this study can improve maternal-infant bonding and women’s experiences of prenatal genetic screening.

Study status: Recruiting

Who can participate: Women over the age of 19, fluent in English, between 26-34 gestation who have chosen to have prenatal genetic screening.

Study results/publication: 

Preliminary results have been presented as an abstract at the 2015 conferences of the National Society of Genetic Counselors and Canadian Association of Genetic Counsellors. The abstract has been published in the Journal of Genetic Counseling: Hippman, C., Austin, J.C. Does a negative prenatal genetic screen result impact maternal-fetal bonding?  Journal of Genetic Counseling. 2015. 24(6). p1086.

Co-Investigator: Jehannine Austin

Funded by: National Society of Genetic Counselors, Prenatal Special Interest Group Grant Award

Consent Form: Pre-MIB Participant Consent Form

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

The TMIST study will help determine whether tomosynthesis results in fewer false-positive findings (reduced recall rate) than traditional 2D mammography.

Principal Investigator: Dr. Paula Gordon

Primary Contact: Melissa Watt, Research Coordinator, 604-875-2424 ext 4878, TMIST@cw.bc.ca

About the study: This study aims to enroll 3,000 women in the Vancouver area into a screening mammography trial. Each woman will be randomized either into a group that receives regular 2-dimensional screening or a new type of screening called Tomosynthesis, which has 3-dimensional capability. Both groups of woman will receive their respective screening mammography exams annually for three years.

Why is this research important? The findings from this study will help determine whether tomosynthesis results in fewer false-positive findings (reduced recall rate) than traditional 2D mammography.  This could result in less anxiety for women who receive abnormal results and lower economic burden of unnecessary follow-up on the health care system.

Study status: Recruiting

Who can participate? Women over the age of 50, fluent in English, Eligible for mammography screening at the Screening Mammography Program of British Columbia, Are able to return to the original sites (BC Women’s Hospital or X-Ray 505) for further screenings.

Co-Investigators: Dr. Linda Warren, Janette Sam, Dr. Andy Coldman, Dr. Joseph Yang.

Funded by: Gordon and Leslie Diamond family/BC Women’s Hospital & Health Centre Foundation

Partners: BC Women’s Hospital + Health Centre, BC Cancer Agency, Screening Mammography Program of BC, American College of Radiology (ACR), American College of Radiology Imaging Network (ACRIN)

HPV FOCAL Study

A clinical trial conducted within the BC Cervical Cancer Screening Program. HPV FOCAL evaluated the effectiveness and safety of HPV testing compared to the Pap test for cervical cancer prevention.

Principal Investigators: Dr. Gina Ogilvie, Dr. Andrew Coldman

Primary Contact: Laurie Smith RN BN MPH, Manager, HPV FOCAL Study, BC Cancer Agency, Direct line: 604-877-6000 x 4829, Study Centre: 1-877-707-5955, laurie.smith@bccancer.bc.ca

About the study: A clinical trial conducted within the BC Cervical Cancer Screening Program. HPV FOCAL evaluated the effectiveness and safety of HPV testing compared to the Pap test for cervical cancer prevention. The study recruited over 25,000 BC women, aged 25-65 engaged in cervical cancer screening. Women were randomly assigned to receive the standard of care, cytology (Pap) testing and managed according to provincial guidelines, or they were assigned to primary HPV testing with management determined by the results of HPV testing.

Why is this research important? Research around the world has shown HPV testing has the potential to improve the performance of cervical screening programs, thereby enhancing cervical cancer prevention. However, high quality Canadian research studies were needed for public health policy formulation within Canada. There is general agreement within the public health community that large scale randomised controlled trials (RCTs) are required for this purpose. As a result, HPV FOCAL was conducted within the BC organized screening program.

Study status: All trial procedures are complete and final results are being published in various scientific journals. See “Study results/Publications” section for more information.

News coverage: 

Study results/publications: 

Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 MonthsThe HPV FOCAL Randomized Clinical Trial. JAMA. 2018;320(1):43–52. doi:10.1001/jama.2018.7464

Ogilvie GS, Smith LW, van Niekerk D, Khurshed F, Pedersen HN, Taylor D, Thomson K, Greene SB, Babich SM, Franco EL, Coldman AJ. Correlates of women’s intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval. BMC Public Health. 2016;16(1):213.

Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, Coldman AJ, Ogilvie GS, Krajden M. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer. 2015;15:968.

Coldman AJ, Phillips N, van Niekerk D, Smith L, Krajden M, Cook D, Quinlan DJ, Ehlen T, Miller D, Stuart GC, Peacock S, Elwood Martin R, Franco EL, Ogilvie G. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program. J Obstet Gynaecol Can. 2015;37(5):412-20.

Smith LW, Khurshed F, van Niekerk DJ, Krajden M, Greene SB, Hobbs S, Coldman AJ, Franco EL, Ogilvie GS. Women’s intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program. BMC Public Health. 2014;14:1060.

Regier DA, van der Hoek K, Ogilvie G, Smith L, Henwood E, Miller DM, McTaggart-Cowan H, Peacock SJ. Exploring colposcopists’ attitudes towards use of HPV testing as a primary screening tool for cervical cancer in British Columbia. J Obstet Gynaecol Can. 2013 Jul;35(7):657-63.

Ogilvie GS, Smith LW, van Niekerk DJ, Khurshed F, Krajden M, Saraiya M, Goel V, Rimer BK, Greene SB, Hobbs S, Coldman AJ, Franco EL. Women’s intentions to receive cervical cancer screening with primary human papillomavirus testing. Int J Cancer. 2013;133(12):2934-43.

Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial — the HPV FOCAL Study. Br J Cancer. 2012;107(12):1917-24.

Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, Peacock SJ, Smith LW, Kan L, Cook DA, Mei W, Stuart GC, Franco EL, Coldman AJ. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111.

Co-Investigators: Dirk van Niekerk, Eduardo Franco, Mel Krajden, Marette Lee, Kathy Ceballos; Gavin Stuart; Ruth Martin; Stuart Peacock.

Funded by: CIHR

Partners: BC Cancer Agency, BC Centre for Disease Control,  BCCDC  BC Public Health & Microbiology Reference Laboratory

Website: http://www.bccancer.bc.ca/our-research/participate/cervical-screening

Quadrivalent vaccine evaluation study (QUEST)

QUEST (Quadrivalent HPV Vaccine Evaluation Study) is a Canada-wide study designed to evaluate whether 2 doses of the HPV vaccine are just as effective as 3 doses at preventing Human Papillomavirus (HPV) infection and cervical cancer.

Principal Investigators: Drs. Gina Ogilvie, Simon Dobson

Primary Contact: QUESTION Coordinating Centre, 604.875.2636 (Toll Free: 1-866-502-2424), questhpvstudy@cfri.ca

About the Study: QUEST (Quadrivalent HPV Vaccine Evaluation Study) is a Canada-wide study designed to evaluate whether 2 doses of the HPV vaccine are just as effective as 3 doses at preventing Human Papillomavirus (HPV) infection and cervical cancer. The QUEST study will seek to recruit 8,666 females from across between the ages of 14 to 18.  Study sites are in British Columbia, Alberta, Quebec, Nova Scotia, and PEI.

Why is the study important? A 2 dose schedule instead of 3 doses of the HPV vaccine means girls would  have to endure fewer shots and the program could be extended to more people including boys.  Fewer doses means that middle and lower income countries are more likely to be able to afford the HPV vaccine program.

Who can participate? Females 14-18 years old who received either 2 or 3 doses of the HPV vaccine on the provincial schedule who are located in BC, Alberta, Quebec, PIE or Nova Scotia.

What does participation involve? Participating is quick and simple and can be done from anywhere.  Participants are enrolled in the study for 5 years and involves completing an online survey  once a year and providing self collected swabs twice a year

Study Results/Publication: 

Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. Int J Cancer. 2015;137(8):1931-7.

Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, Karunakaran K, Kollmann T, Ogilvie G, Petric M, Dobson S. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine. 2014;32(5):624-30.

Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-802.

Co-Investigators: Mel Krajden, Joel Singer, Marie Helene Mayrand, Shelly McNeil, Chantal Sauvageau, Vladmir Gilca, James Kellner, Deborah Money

Funded by: MSFHR, CIHR

Partners: UBC, CFRI, Dalhousie University, University of Calgary, Centre Hospitalier Universitaire de Quebec

Websites:

http://questhpvstudy.ca/contact-us/

http://questhpvstudy.ca/

Long Term Follow-up Study of CTN 236 – A Study of an HPV VLP Vaccine in a Cohort of HIV Positive Girls and Women

This study aims to better understand how the HPV vaccine works in HIV positive girls and women over the long term and to clarify how care can be provided to best protect this population from HPV infection and associated cervical cancer and genital warts.

Principal Investigator: Dr. Deborah Money

Primary Contact: Nancy Lipsky, WHRI Research Manager, 604 875 2000 x4877, NLipsky@cw.bc.ca

About the study: Infection with human papillomavirus (HPV) is the leading cause of cervical cancer and genital warts.  This study extends follow-up of girls and women who received a least one human papillomavirus (HPV) vaccine through the first phase of this research.  353 girls and women from across Canada are therefore eligible and are asked to participate in 3 approximately annual study visits.  At each visit, participant health status is reviewed and blood samples and vaginal swabs are taken to assess response to the HPV vaccine and efficacy of the vaccine in preventing HPV infection and associated diseases over time.

Why is this research important? This research is important because, while the HPV vaccine has been studied extensively in women and girls without HIV, this is one of the first projects to investigate response to the HPV vaccine in girls and women living with HIV.  Generally, persons living with HIV do not respond as well to standard vaccines compared to persons without HIV. Further, Women with HIV have four times higher rates of HPV infection and are much more likely to progress from infection to cervical cancer.  Cervical cancer is responsible for approximately 266,000 deaths globally per year.  This research can help us better understand how the vaccine works in HIV positive girls and women over the long term and can clarify how care can be provided to best protect this population from HPV infection and associated cervical cancer and genital warts.

Study status: Recruitment is limited to girls and women who participated in the first phase of this research.  Eligible women will be recruited throughout the study duration.

Who can participate: Those who 1) received at least one HPV vaccine through CTN 236, phase 1 and 2) who are able to give fully informed consent or assent.

News:

  • Canadian HIV Trials Network (CTN) article on adult participants’ response to the vaccine (2016)
  • Interview by Suzanne MacCarthy. The Positive Side Magazine. Will the HPV Vaccine Guard You? Spring/Summer 2009, PAGES 13-14

Study results/publication: Enrollment and data collection for this follow-up study are ongoing and results are pending.  However, in the first phase of this research, the HPV vaccine was well tolerated, with no safety concerns identified.  Girls and women showed a solid immune response to the vaccine- this suggests ability of the vaccine to protect HIV positive girls and women from HPV infection.  Observed low rates of new HPV infection, genital warts and precancerous changes to the cervix in the 2 years following vaccination further reflect short-term efficacy of the HPV vaccine in this group.  Girls ages 9-14 did not produce as strong an immune response to the vaccine as did comparable girls without HIV; longer term follow up is important to better understand the level of protection provided by the HPV vaccine to girls and women who are a living with HIV.

Co-Investigators & Collaborators: Dr. Neora Pick (University of British Columbia), Dr. Mel Krajden (University of British Columbia), Dr. Gina Ogilvie (University of British Columbia), Dr. Simon R.M. Dobson (University of British Columbia), Dr. Marianne Harris (University of British Columbia), Dr. Fiona Smaill (McMaster University), Dr. Lindy Samson (Children’s Hospital of Eastern Ontario), Dr. Sean Ari Bitnun (University of Toronto), Dr. Mona Loutfy (Women’s College Research Institute), Dr. Fatima Kakkar (Universite de Montreal), Dr. Mark Yudin (University of Toronto), Dr. Sharon Walmsley (University of Toronto), Dr. Marina Klein (McGill University), Dr. Francois Coutlee (Universite de Montreal), Dr. Janet Hill (University of Saskatchewan), Dr. Janet Raboud (University of Toronto), Dr. Wendy Wobeser (Queen’s University), Dr. Sylvie Trottier (Universite Laval), Dr. Catherine Hankins (University of Amsterdam), Dr. Normand Lapointe (Hopital Sainte Justine), Dr. Darrell Tan (University of Toronto), Dr. Jason Brophy (University of Ottawa), Dr. Andrew Coldman (BC Cancer Agency), Dr. Angela Kaida (Simon Fraser University), Dr. Arianne Alimenti (University of British Columbia), Dr. Christos Karatzios (University of Montreal), Dr. Dirk van Niekirk (BC Cancer Agency), Dr. Jan Christilaw (BC Women’s Hospital and Health Centre), Dr. Jeff Cohen (HIV Care Program, Ontario), Dr. Joel Singer (Canadian HIV Trials Network), Dr. Julie van Schalkwyk (University of British Columbia), Ms. Laurie Edmiston (CATIE), Ms. Marcie Summers (Positive Women’s Network).

Funded by: Canadian Institutes of Health Research and further supported by the Canadian HIV Trials Network.

Clinical sites include: Oak Tree Clinic, BC Women’s Hospital and Health Centre, Vancouver, BC; St. Paul’s Infectious Disease Clinic, Vancouver, BC; Toronto General Hospital, Toronto, ON; Maple Leaf Medical Clinic, Toronto, ON; St. Michaels Hospital, Toronto, ON; Hospital for Sick Children, Toronto, ON; McMaster University Hospital, Hamilton, ON; Kingston General, Kingston, ON; Children’s Hospital of Eastern Ontario, Ottawa, ON; HIV Care Program, Windsor, ON; McGill University Health Centre, Montreal, QB; Montreal Children’s Hospital, Montreal, QB; CHU Sainte Justine, Montréal, QB; Centre Hospitalier de l’Université Laval, Québec City, QB;

Statistical Analyses: Dr. Janet Raboud, University Health Network

Data Management: Canadian HIV Trials Network

Lab Analyses: Dr. Francois Coutlee, University of Montreal; Dr. Janet Hill, University of Saskatchewan; British Columbia Centre for Disease Control; Merck (pharmaceuticals).

CARMA-1-PREG

CARMA-1-PREG is investigating factors related to pre-term deliveries among HIV positive women.

Principal Investigator: Dr. Deborah Money

Mitochondrial and Telomere Studies in Pregnancy
– AND –
Placental Mitochondrial Toxicity in HIV Therapy during Pregnancy
– AND –
Measuring Mitochondrial Aging, Application to HIV Infection and Therapy AND Cellular Aging and HIV Comorbidities in Women and Children

(CARMA-1-PREG)


Primary Contact: Evelyn Maan, Research Manager, 604-875-2000 ext. 2463, emaan@cw.bc.ca

About the study: CARMA-1-PREG is investigating factors related to pre-term deliveries among HIV positive women. Research has shown that HIV+ pregnant women are 2x more likely to deliver their babies early (more than 3 weeks before their due dates), compared to women without HIV. The purpose of CARMA-1-PREG is to study the effects of particular anti-HIV medications on pregnant women and on their infants by examining two markers of cell function: the length of DNA at the ends of chromosomes (“telomeres”) and the energy producing parts of the cell (“mitochondrial DNA”). CARMA-1-PREG also investigates how HIV, anti-HIV medications and other factors (e.g. the bacterial environment of a pregnant woman’s vagina) may affect early delivery.

Why is this research important?  Anti-HIV medication has dramatically reduced the risk of infants getting HIV from their HIV+ mothers (from 25% to less than 1%). However, research has demonstrated that HIV+ pregnant women are twice as likely to have a pre-term delivery when compared to women without HIV. Better understanding the factor(s) which cause these pre-term deliveries among HIV+ women is integral to the health of mothers and infants living with or exposed to HIV.

Study status: Recruiting

Who can participate: Pregnant women living with HIV who are taking, or are going to be taking, anti-HIV medication during their pregnancy.

Study Results/Publications: 

Money DM, Wagner EC, Maan EJ, Chaworth-Musters T, Gadawski I, van Schalkwyk JE, Forbes JC, Burdge D, Albert AYK, Lohn Z, Côté HCF, and The Oak Tree Clinic Research Group “Evidence of subclinical mtDNA alterations in HIV-infected pregnant women receiving combination antiretroviral therapy compared to HIV-negative pregnant women” PLoS One. 2015 Aug 6;10(8):e0135041. doi: 10.1371/journal.pone.0135041. eCollection 2015.

Imam T, Jitratkosol MH, Soudeyns H, Sattha B, Gadawski I, Maan E, Forbes JC, Alimenti A, Lapointe N, Lamarre V, Money DM, Côté HC; CIHR Emerging Team Grant on HIV Therapy and Aging: CARMA. Leukocyte telomere length in HIV-infected pregnant women treated with antiretroviral drugs during pregnancy and their uninfected infants. J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):495-502. PMID: 22580562

Jitratkosol MH, Sattha B, Maan EJ, Gadawski I, Harrigan PR, Forbes JC, Alimenti A, van Schalkwyk J, Money DM, Côté HC; CIHR Emerging Team Grant on HIV Therapy and Aging (CARMA). Blood mitochondrial DNA mutations in HIV-infected women and their infants exposed to HAART during pregnancy. AIDS. 2012 Mar 27;26(6):675-83. PMID: 22436539

Co-Investigators: Dr. Helene Cote, Dr. Julie van Schalkwyk, Dr. Isabelle Boucoiran, Dr. Melanie Murray, Dr. Ariane Alimenti, Dr. Neora Pick

Funded by: CIHR

Partners: Positive Women’s Network

CARMA 1 Participant Consent Form

CARMA 7: Bone and Renal Outcomes in HIV-Exposed, Uninfected Infants with Perinatal Exposure to Tenofovir

The purpose of CARMA 7 is to investigate how fetal exposure to the anti-HIV medication Tenofovir may affect the bone and kidney health of infants who are born to HIV+ women.

Principal Investigator: Dr. Ariane Alimenti

Primary Contract: Evelyn Maan, Research Manager, 604-875-2000 ext. 2463, emaan@cw.bc.ca

About the Study: Anti-HIV medication has reduced the risk of HIV transmission from mother to child from 25% to less than 1%. However, the effects of some of these anti-HIV medications on the developing fetus have not yet been thoroughly studied. One medication in particular, called “Tenofovir”, can cause some bone and kidney problems for HIV+ adults when taken for a long time, especially with existing bone and kidney diseases. The purpose of CARMA 7 is to investigate how fetal exposure to Tenofovir may affect the bone and kidney health of infants who are born to HIV+ women.

Why is this research important? The use of Tenofovir is becoming far more common in anti-HIV medication regimens because it is so well tolerated. As a result, an increasing number of women are getting pregnant while taking this particular medication (almost 25% of HIV+ pregnancies in BC in 2011). Accordingly, it is very important for the current and future health of infants born to HIV+ women to study the effects of this anti-HIV medication.

Study Status: Recruiting

Who can participate:  Infants who do not have HIV, born at term (>35 weeks +2 days) to an HIV+ mother who took anti-HIV medication during her pregnancy, specifically Tenofovir, Abacavir, or Zidovudine (the last two for the control group).  Infants have visits for the CARMA-7 study at 1 month, 6 months, and 18 months of age.

Co-Investigators: Dr. Helene Cote, Dr. Deborah Money, Dr. Laura Sauve, Dr. Jason Brophy

Funded by: CIHR, Canadian HIV Trials Network

CARMA 7 Participant Consent Form

Personalized Contraception for Canadians – Decision analytic modelling to support women-centered choices

Personalized Contraception for Canadians- Decision analytic modelling to support women-centered choices

Principal Investigator: Dr. Flora Teng

Primary Contact: Weihong Chen, Research Coordinator, 604-875-2424 x 4894, Weihong.chen@ubc.ca

About the study: This study will develop and pilot test a Canadian woman-centered contraception decision-making mobile application. This app will be “effectiveness-based” and will incorporate factors women consider important when choosing a contraceptive. Mixed methods will be used including focus groups and interviews to select design elements and feature priorities and to inform iterative pilot testing and improvement cycles of the application. Operations Research methods will be utilized to design decision pathways, and software engineering will be used to enhance usability and human-computer interaction.

Why is this research important? This study aims to enable women to make contraceptive choices that are highly effective and optimal fit to personal preferences. Therefore, they will be able to continue their chosen method, achieve their reproductive goals, and minimize risk of unintended pregnancy.

Study status: We have conducted several focus groups to understand the most important and relevant decision criteria in choosing contraception from the perspective of Canadian women. This qualitative data is being analyzed and will be used to create a survey that will specifically rank the contraception priorities of women. The survey will be pilot tested with 120-150 women aged 14-49. Results of the survey will be translated into the Decision-Making model to build the electronic application.

Co-Investigators: Wendy Norman, Saied Samiedaluie, Tymarah Colewah

Funded by: Women’s Health Research Institute

MIST (Mindfulness, Incontinence and Sexual function Treatment) Study Research Proposal for a Pilot Study

MIST (Mindfulness, Incontinence and Sexual function Treatment) Study Research Proposal for a Pilot Study

Principal Investigators: Dr. Maryse Larouche/Dr. Geoffrey Cundiff

Primary Contact: Nicole Koenig, Research Coordinator, 604-806-9829, nkoenig@providencehealth.bc.ca

About the study: This study aims to determine if there is an impact on sexual distress using mindfulness-based sex therapy (MBST) in addition to standard urogynecologic care, in women with both urinary incontinence (UI) and sexual dysfunction.

Why is this research important? Urinary Incontinence is prevalent among women and has a significant impact on physical, emotional and mental well-being, including distressing effects on sexual health. Poor sexual health has been associated with lower health related quality of life, and depressed mood. Given the impact that sexual function can have, it is of utmost importance that research in this area is expanded. Mindfulness-based therapy has been used successfully to treat women with sexual dysfunctions. Our pilot study will be the first step in determining its role in women with Urinary incontinence and sexual dysfunction.

Study status: Currently the research study is obtaining ethics approval with recruitment starting upon research ethics approval.

Who can participate: Patients (Women 19 years of age and older) who attend the Centre for Pelvic Floor at St. Paul’s Hospital and present with both urinary incontinence and sexual dysfunction.

Co-Investigators: Dr. Lori Brotto, Dr. Roxana Geoffrion

Funded by: Sexual Medicine Society of North America